Skip to main content Accessibility help

Host–microbiome interactions in human type 2 diabetes following prebiotic fibre (galacto-oligosaccharide) intake

  • Camilla Pedersen (a1), Edith Gallagher (a2), Felicity Horton (a2), Richard J. Ellis (a3), Umer Z. Ijaz (a4), Huihai Wu (a1), Etana Jaiyeola (a1), Onyinye Diribe (a1), Thibaut Duparc (a5), Patrice D. Cani (a5), Glenn R. Gibson (a6), Paul Hinton (a2), John Wright (a1) (a7), Roberto La Ragione (a1) and M. Denise Robertson (a1)...


Aberrant microbiota composition and function have been linked to several pathologies, including type 2 diabetes. In animal models, prebiotics induce favourable changes in the intestinal microbiota, intestinal permeability (IP) and endotoxaemia, which are linked to concurrent improvement in glucose tolerance. This is the first study to investigate the link between IP, glucose tolerance and intestinal bacteria in human type 2 diabetes. In all, twenty-nine men with well-controlled type 2 diabetes were randomised to a prebiotic (galacto-oligosaccharide mixture) or placebo (maltodextrin) supplement (5·5 g/d for 12 weeks). Intestinal microbial community structure, IP, endotoxaemia, inflammatory markers and glucose tolerance were assessed at baseline and post intervention. IP was estimated by the urinary recovery of oral 51Cr-EDTA and glucose tolerance by insulin-modified intravenous glucose tolerance test. Intestinal microbial community analysis was performed by high-throughput next-generation sequencing of 16S rRNA amplicons and quantitative PCR. Prebiotic fibre supplementation had no significant effects on clinical outcomes or bacterial abundances compared with placebo; however, changes in the bacterial family Veillonellaceae correlated inversely with changes in glucose response and IL-6 levels (r −0·90, P=0·042 for both) following prebiotic intake. The absence of significant changes to the microbial community structure at a prebiotic dosage/length of supplementation shown to be effective in healthy individuals is an important finding. We propose that concurrent metformin treatment and the high heterogeneity of human type 2 diabetes may have played a significant role. The current study does not provide evidence for the role of prebiotics in the treatment of type 2 diabetes.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Host–microbiome interactions in human type 2 diabetes following prebiotic fibre (galacto-oligosaccharide) intake
      Available formats

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Host–microbiome interactions in human type 2 diabetes following prebiotic fibre (galacto-oligosaccharide) intake
      Available formats

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Host–microbiome interactions in human type 2 diabetes following prebiotic fibre (galacto-oligosaccharide) intake
      Available formats


Corresponding author

* Corresponding author: Dr M. D. Robertson, fax +44 1483 688 501, email


Hide All
1. Cani, PD, Amar, J, Iglesias, MA, et al. (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 17611772.
2. Cani, PD, Bibiloni, R, Knauf, C, et al. (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57, 14701481.
3. Horton, F, Wright, J, Smith, L, et al. (2014) Increased intestinal permeability to oral chromium (51Cr)-EDTA in human type 2 diabetes. Diabet Med 31, 559563.
4. Creely, SJ, McTernan, PG, Kusminski, CM, et al. (2007) Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 292, E740E747.
5. Pussinen, PJ, Havulinna, AS, Lehto, M, et al. (2011) Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care 34, 392397.
6. Ghoshal, S, Witta, J, Zhong, J, et al. (2009) Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res 50, 9097.
7. Larsen, N, Vogensen, FK, van den Berg, FW, et al. (2010) Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE 5, e9085.
8. Wu, X, Ma, C, Han, L, et al. (2010) Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol 61, d69d78.
9. Karlsson, FH, Tremaroli, V, Nookaew, I, et al. (2013) Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498, 99103.
10. Remely, M, Aumueller, E, Jahn, D, et al. (2014) Microbiota and epigenetic regulation of inflammatory mediators in type 2 diabetes and obesity. Benef Microbes 5, 3343.
11. Sato, J, Kanazawa, A, Ikeda, F, et al. (2014) Gut dysbiosis and detection of ‘live gut bacteria’ in blood of Japanese patients with type 2 diabetes. Diabetes Care 37, 23432350.
12. Lambeth, SM, Carson, T, Lowe, J, et al. (2015) Composition, diversity and abundance of gut microbiome in prediabetes and type 2 diabetes. J Diabetes Obes 2, 17.
13. Mattace Raso, G, Simeoli, R, Iacono, A, et al. (2014) Effects of a Lactobacillus paracasei B21060 based synbiotic on steatosis, insulin signaling and toll-like receptor expression in rats fed a high-fat diet. J Nutr Biochem 25, 8190.
14. Wang, Z, Xiao, G, Yao, Y, et al. (2006) The role of bifidobacteria in gut barrier function after thermal injury in rats. J Trauma 61, 650657.
15. Everard, A, Belzer, C, Geurts, L, et al. (2013) Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci 110, 90669071.
16. Pourghassem Gargari, B, Dehghan, P, Aliasgharzadeh, A, et al. (2013) Effects of high performance inulin supplementation on glycemic control and antioxidant status in women with type 2 diabetes. Diabetes Metab J 37, 140148.
17. Yamashita, K, Kawai, K & Itakura, M (1984) Effects of fructo-oligosaccharides on blood glucose and serum lipids in diabetic subjects. Nutr Res 4, 961966.
18. Alles, MS, de Roos, NM, Bakx, JC, et al. (1999) Consumption of fructooligosaccharides does not favorably affect blood glucose and serum lipid concentrations in patients with type 2 diabetes. Am J Clin Nutr 69, 6469.
19. Luo, J, Van Yperselle, M, Rizkalla, SW, et al. (2000) Chronic consumption of short-chain fructooligosaccharides does not affect basal hepatic glucose production or insulin resistance in type 2 diabetics. J Nutr 130, 15721577.
20. Aliasgharzadeh, A, Dehghan, P, Gargari, BP, et al. (2015) Resistant dextrin, as a prebiotic, improves insulin resistance and inflammation in women with type 2 diabetes: a randomised controlled clinical trial. Br J Nutr 113, 321330.
21. Gargari, BP, Namazi, N, Khalili, M, et al. (2015) Is there any place for resistant starch, as alimentary prebiotic, for patients with type 2 diabetes? Complement Ther Med 23, 810815.
22. Dehghan, P, Farhangi, MA, Tavakoli, F, et al. (2016) Impact of prebiotic supplementation on T-cell subsets and their related cytokines, anthropometric features and blood pressure in patients with type 2 diabetes mellitus: a randomized placebo-controlled Trial. Complement Ther Med 24, 96102.
23. Vulevic, J, Juric, A, Walton, GE, et al. (2015) Influence of galacto-oligosaccharide mixture (B-GOS) on gut microbiota, immune parameters and metabonomics in elderly persons. Br J Nutr 114, 586595.
24. Davis, LM, Martinez, I, Walter, J, et al. (2011) Barcoded pyrosequencing reveals that consumption of galactooligosaccharides results in a highly specific bifidogenic response in humans. PloS ONE 6, e25200.
25. Teshima, CW & Meddings, JB (2008) The measurement and clinical significance of intestinal permeability. Curr Gastroenterol Rep 10, 443449.
26. Bodinham, CL, Smith, L, Wright, J, et al. (2012) Dietary fibre improves first-phase insulin secretion in overweight individuals. PLOS ONE 7, e40834.
27. Friedewald, WT, Levy, RI & Fredrickson, DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18, 499502.
28. Ellis, RJ, Bruce, KD, Jenkins, C, et al. (2013) Comparison of the distal gut microbiota from people and animals in Africa. PLOS ONE 8, e54783.
29. Caporaso, JG, Kuczynski, J, Stombaugh, J, et al. (2010) QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7, 335336.
30. Quince, C, Lanzen, A, Davenport, RJ, et al. (2011) Removing noise from pyrosequenced amplicons. BMC Bioinformatics 12, 38.
31. Quince, C, Lanzén, A, Curtis, TP, et al. (2009) Accurate determination of microbial diversity from 454 pyrosequencing data. Nat Methods 6, 639641.
32. Wang, Q, Garrity, GM, Tiedje, JM, et al. (2007) Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 73, 52615267.
33. Davis, LM, Martinez, I, Walter, J, et al. (2010) A dose dependent impact of prebiotic galactooligosaccharides on the intestinal microbiota of healthy adults. Int J Food Microbiol 144, 285292.
34. Walton, GE, van den Heuvel, EG, Kosters, MH, et al. (2012) A randomised crossover study investigating the effects of galacto-oligosaccharides on the faecal microbiota in men and women over 50 years of age. Br J Nutr 107, 14661475.
35. Alles, MS, Hartemink, R, Meyboom, S, et al. (1999) Effect of transgalactooligosaccharides on the composition of the human intestinal microflora and on putative risk markers for colon cancer. Am J Clin Nutr 69, 980991.
36. Johnston, KL, Thomas, EL, Bell, JD, et al. (2010) Resistant starch improves insulin sensitivity in metabolic syndrome. Diabet Med 27, 391397.
37. Bodinham, CL, Smith, L, Thomas, EL, et al. (2014) Efficacy of increased resistant starch consumption in human type 2 diabetes. Endocr Connect 3, 7584.
38. Napolitano, A, Miller, S, Nicholls, AW, et al. (2014) Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLOS ONE 9, e100778.
39. Lee, H & Ko, G (2014) Effect of metformin on metabolic improvement and the gut microbiota. Appl Environ Microbiol 80, 59355943.
40. Shin, NR, Lee, JC, Lee, HY, et al. (2014) An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63, 727735.
41. Mithieux, G, Rajas, F & Zitoun, C (2006) Glucose utilization is suppressed in the gut of insulin-resistant high fat-fed rats and is restored by metformin. Biochem Pharmacol 72, 17571762.
42. Moreno-Navarrete, JM, Ortega, F, Serino, M, et al. (2012) Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int J Obes 36, 14421449.
43. Forslund, K, Hildebrand, F, Nielsen, T, et al. (2015) Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528, 262266.
44. Catry, E, Pachikian, BD, Salazar, N, et al. (2015) Ezetimibe and simvastatin modulate gut microbiota and expression of genes related to cholesterol metabolism. Life Sci 132, 7784.
45. Walker, AW & Lawley, TD (2012) Therapeutic modulation of intestinal dysbiosis. Pharmacol Res 69, 7586.
46. Kettle, H, Louis, P, Holtrop, G, et al. (2015) Modelling the emergent dynamics and major metabolites of the human colonic microbiota. Environ Microbiol 17, 16151630.
47. Byrne, CS, Chambers, ES, Morrison, DJ, et al. (2015) The role of short chain fatty acids in appetite regulation and energy homeostasis. Int J Obes (Lond) 39, 13311338.


Type Description Title
Supplementary materials

Pedersen supplementary material
Figure S1

 PDF (90 KB)
90 KB
Supplementary materials

Pedersen supplementary material
Figure S2

 PDF (96 KB)
96 KB
Supplementary materials

Pedersen supplementary material
Figure S3

 PDF (234 KB)
234 KB
Supplementary materials

Pedersen supplementary material
Pedersen supplementary material 1

 PDF (160 KB)
160 KB


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed